Inhibikase Therapeutics Inc (IKT) Stock Analysis

AI analysis of Inhibikase Therapeutics Inc (IKT)

Hold

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.

Valuation Metrics

The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT) is 0.00, compared to its 5-year average forward P/E of -2.42.

Forward P/E

Overvalued

5Y Average P/E

-2.42

Current P/E

0.00

Overvalued

-0.53

Undervalued

-4.32

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Overvalued

5Y Average P/S

150.84

Current P/S

826.05

Overvalued

463.07

Undervalued

-161.39

Alphio AI Price Scenarios for IKT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IKT

$2.41

Scenario price

B

Base

Base · 50%IKT

$2.22

Scenario price

B

Bear

Bear · 25%IKT

$2.07

Scenario price

Whales holding IKT

B

Blackstone Alternative Investment Advisors LLC

+ HoldingIKT

-0.88%

3M Return

S

Soleus Capital Management, L.P.

+ HoldingIKT

-7.34%

3M Return

A

ADAR1 Capital Management, LLC

+ HoldingIKT

-14.25%

3M Return

IKT FAQ — answered by Alphio AI

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.